The Effect of Erythropoietin Therapy and Hemoglobin Levels on the Immune Response to Engerix-B Vaccination in Chronic Kidney Disease

References

• Haubitz M., Ehlerding G., Beigel A., Heuer U., Hemmerling A.E., Thoma H.A. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin. Nephrol. 1996; 45: 180–182
   Google Scholar
• Kunori T., Fehrman I., Ringden O., Moller E. In vitro characterization of immunological responsiveness of uremic patients. Nephron 1980; 26: 234–239
   Google Scholar
• Raska K., Jr., Raskova J., Shea S.M., Frankel R.M., Wood R.H., Lifter J., Ghorial I., Eisinger R.P., Homer L. T cell subsets and cellular immunity in end-stage renal disease. Am. J. Med. 1983; 75: 734–740
   Google Scholar
• Chatenoud L., Dugas B., Beaurain G., Touam M., Drueke T., Vasquez A., Galanaud P., Bach J.F., Delfraissy J.F. Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc. Nath. Acad. Sci. USA 1986; 83: 7457–7461
   Google Scholar
• Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985; 135: 3172–3177
   Google Scholar
• Seaworth B., Drucker J., Starling J., Drucker R., Stevens C., Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. J. Infect. Dis. 1988; 157: 332–337
   Google Scholar
• Hadler S., Francis D., Maynard J., Thompson S.E., Judson F.N., Echenberg D.F., Ostrow D.G., Mally P.M., Penley K.A., Altman N.L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 1986; 315: 209–214
   Google Scholar
• Eddleston A. Modern vaccines: hepatitis. Lancet 1990; 335: 1142–1145
   Google Scholar
• Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., Sadovsky R., Morrison J.M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 1980; 303: 833–841
   Google Scholar
• Stevens O.E., Szmuness W., Goodman A.I., Weseley S.A., Fotino M. Hepatitis B vaccine immune response in hemodialysis patients. Lancet 1980; 11: 1211–1213
   Google Scholar
• Pasko M.R., Bartholomew W.R., Beam T.R., Amsterdam D., Cunningham E.E. Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am. J. Kidney Dis. 1988; 11: 326–331
   Google Scholar
• Jilg W., Schmidt M., Weinel B., Kuttler T., Brass H., Bromer J., Muller R., Schulte B., Schwarzbeck A., Deinhardt F. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J. Hepatol. 1986; 3: 1900–1905
   Google Scholar
• Fernandez E., Betriu M.A., Gomez R., Montoliu J. Response to the hepatitis B virus vaccine in hemodialysis patients: influence of malnutrition and is importance as a risk factor for morbidity and mortality. Nephrol. Dial. Transplant. 1996; 12: 623–624
   Google Scholar
• Navarro J.F., Teruel J.L., Mateos M.L., Marcen R., Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am. J. Nephrol. 1996; 16: 1695–1697
   Google Scholar
• Mettang T., Schenk U., Thomas S., Machleidt C., Kiefer T., Fisher F.P., Kuhlmann U. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron. 1996; 72: 192–196
   Google Scholar
• Ayli M.D., Ensari C., Ayli M., Mandioglu Mut S. Effect of levamidasole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron 2000; 84: 291–292
   Google Scholar
• Ozener C., Fak A.S., Avsar E., Cinar S., Lawrence R., Akoglu E. The effect of alpha interferon therapy and short-interval intradermal administration on response to hepatitis B vaccine in haemodialysis patients. Nephrol. Dial. Transplant. 1999; 14: 1339–1340
   Google Scholar
• Mauri J.M., Valles M. Effect of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responer, chronic uraemic patients. Nephrol. Dial. Transplant. 1997; 12: 729–732
   Google Scholar
• Anandh U., Bastani B., Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am. J. Nephrol. 2000; 20: 53–56
   Google Scholar
• Carol S.D., Alan C.S., James F.S., Hamilton J.D. Hepatitis B vaccination and booster in predialysis patients: a 4-years analysis. Vaccine 1993; 11: 1229–1232
   Google Scholar
• Fraser G.M., Ohana N., Fenyves D., Neumann L., Chazan R., Niv Y., Niv Y., Chaimovitch S. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J. Hepatol. 1994; 21: 450–454
   Google Scholar
• Krantz S.B. Erythropoietin. Blood 1991; 77: 419–434
   Google Scholar
• Kimata H., Yoshida A., Ishioka C., Masuda S., Sasaki R., Mikana H. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum free medium. Exp. Immunol. 1991; 85: 151–156
   Google Scholar
• Huraib S., Abu Aisha H., Al Momen A., Al Wakeel J., Memon N., Al Tuwaijri A. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am. J. Kidney Dis. 1997; 29: 866–870
   Google Scholar
• Shurtz Swirski R., Kristal B., Shkolnik T., Weissman I., Shapiro G., Shasha S.M. Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 1996; 72: 27–29
   Google Scholar